Direct to healthcare professional communication (DHPC) letter regarding pseudoephedrine 

Following an EU-wide review, and a review by the Medicines and Healthcare products Regulatory Agency (MHRA) of UK reports, with advice from the Pharmacovigilance Expert Advisory Group (PEAG) of the Commission on Human Medicines (CHM), it has been concluded that pseudoephedrine is associated with risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS). 

A DHPC letter has been sent to healthcare providers from PAGB on behalf of the Marketing Authorisation Holders of medicines containing pseudoephedrine, including a summary of MHRA’s notice and background on the safety concern, with an overview of PRES and RCVS. 

For further details, read the letter. 

Related news

Self-Care Week blog post from Mark Burdon

Our final blog post this Self-Care Week delves into the pivotal role that pharmacies are playing in the Government’s 10 Year Health Plan. Mark explores the impact of Pharmacy First paving the way, the current challenges that the Government should be prioritising and how digital tools can bring support pharmacists as they widen access to self-care and help streamline patient journeys.

Self-Care Week blog post from Mark Burdon

Self-Care Week blog post from Michelle Riddalls OBE

To mark Self-Care Week, Michelle Riddalls OBE has authored a blog post on the important role that reclassification has to play in the Government’s agenda to move from sickness to prevention and reduce pressures on primary care. Through greater reclassification of over-the-counter products, we can improve access to self-care, reduce GP visits and empower patients, whilst delivering up to £1.4 billion in savings to NHS prescribing costs annually.

Self-Care Week blog post from Michelle Riddalls OBE
View all